Transcriptomics uncovers substantial variability associated with alterations in manufacturing processes of macrophage cell therapy products

Olga L Gurvich,Katja A Puttonen,Aubrey Bailey,Anssi Kailaanmäki,Vita Skirdenko,Minna Sivonen,Sanna Pietikäinen,Nigel R Parker,Seppo Ylä-Herttuala,Tuija Kekarainen
DOI: https://doi.org/10.1038/s41598-020-70967-2
2020-08-20
Abstract:Gene expression plasticity is central for macrophages' timely responses to cues from the microenvironment permitting phenotypic adaptation from pro-inflammatory (M1) to wound healing and tissue-regenerative (M2, with several subclasses). Regulatory macrophages are a distinct macrophage type, possessing immunoregulatory, anti-inflammatory, and angiogenic properties. Due to these features, regulatory macrophages are considered as a potential cell therapy product to treat clinical conditions, e.g., non-healing diabetic foot ulcers. In this study we characterized two differently manufactured clinically relevant regulatory macrophages, programmable cells of monocytic origin and comparator macrophages (M1, M2a and M0) using flow-cytometry, RT-qPCR, phagocytosis and secretome measurements, and RNA-Seq. We demonstrate that conventional phenotyping had a limited potential to discriminate different types of macrophages which was ameliorated when global transcriptome characterization by RNA-Seq was employed. Using this approach we confirmed that macrophage manufacturing processes can result in a highly reproducible cell phenotype. At the same time, minor changes introduced in manufacturing resulted in phenotypically and functionally distinct regulatory macrophage types. Additionally, we have identified a novel constellation of process specific biomarkers, which will support further clinical product development.
What problem does this paper attempt to address?